Gehan F. Balata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gehan F. Balata has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Al Zahraa G. Al Ashmawy
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Heliopolis University, Cairo 11785, Egypt
1 shared publication - Hanan Mohammed El-Nahas
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt
1 shared publication - Marwa M. Saeed
Lecturer of Pharmacology & Toxicology, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt
1 shared publication - Mohammad Hussain Alyami
Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 66462, Saudi Arabia
1 shared publication - Noura G. Eissa
Badr University in Cairo Research Center, Badr University in Cairo, Badr City, Cairo 11829, Egypt
1 shared publication - Shaimaa H. El-Fayoumi
Lecturer of Pharmacology & Toxicology, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 17 September 2026
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 12 (1) , 89
Role of repurposed drugs and herbal medicines to improve cognitive deficit in postmenopausal Alzheimer's disease: a systematic review of preclinical evidence
Alzheimer's disease (AD) disproportionately affects postmenopausal women, most likely due to hormonal changes that cause early neuropathological alterations. The ovariectomized/ d -galactose (OVX/ d -gal) model provides a dependable platform to replicate postmenopausal AD pathophysiology in preclinical studies. Menopause-related estrogen loss is becoming more widely acknowledged as a key window for AD development. Despite the growing interest in potential treatments, it is currently unknown how effective herbal remedies and repurposed medications are in this model. This systematic review assessed preclinical data on cognitive outcomes following the administration of these medications in OVX/ d -gal-induced AD. Following the PRISMA guidelines, the research team conducted a systematic search of four databases and extracted the relevant OVX/ d -gal AD studies according to specified inclusion and exclusion criteria, assessed the risk of bias using SYRCLE, and rated the certainty of evidence using GRADE. Seventeen pertinent studies were found after searching Web of Science, PubMed, ScienceDirect, and Scopus. Although both herbal extracts and repurposed medications showed encouraging results in enhancing cognitive function, the overall certainty of the evidence was extremely low, mostly because of small trial numbers, unclear risk of bias, and little reporting on the quality of the methods used. The most promising repurposed medications were escitalopram, telmisartan, dimethyl fumarate, and dapagliflozin, and natural compounds such as ginsenoside Rg1 and resveratrol showed persistent effects and solid mechanistic evidence. While preliminary findings are encouraging, methodological heterogeneity and reporting limitations highlight the urgent need for more robust, well-designed preclinical studies before clinical translation can be considered.
- 17 September 2026
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 12 (1) , 89
Open AccessRole of repurposed drugs and herbal medicines to improve cognitive deficit in postmenopausal Alzheimer's disease: a systematic review of preclinical evidence
Alzheimer's disease (AD) disproportionately affects postmenopausal women, most likely due to hormonal changes that cause early neuropathological alterations. The ovariectomized/ d -galactose (OVX/ d -gal) model provides a dependable platform to replicate postmenopausal AD pathophysiology in preclinical studies. Menopause-related estrogen loss is becoming more widely acknowledged as a key window for AD development. Despite the growing interest in potential treatments, it is currently unknown how effective herbal remedies and repurposed medications are in this model. This systematic review assessed preclinical data on cognitive outcomes following the administration of these medications in OVX/ d -gal-induced AD. Following the PRISMA guidelines, the research team conducted a systematic search of four databases and extracted the relevant OVX/ d -gal AD studies according to specified inclusion and exclusion criteria, assessed the risk of bias using SYRCLE, and rated the certainty of evidence using GRADE. Seventeen pertinent studies were found after searching Web of Science, PubMed, ScienceDirect, and Scopus. Although both herbal extracts and repurposed medications showed encouraging results in enhancing cognitive function, the overall certainty of the evidence was extremely low, mostly because of small trial numbers, unclear risk of bias, and little reporting on the quality of the methods used. The most promising repurposed medications were escitalopram, telmisartan, dimethyl fumarate, and dapagliflozin, and natural compounds such as ginsenoside Rg1 and resveratrol showed persistent effects and solid mechanistic evidence. While preliminary findings are encouraging, methodological heterogeneity and reporting limitations highlight the urgent need for more robust, well-designed preclinical studies before clinical translation can be considered.
- Open Access
- 3 November 2023
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 12 (1) , 167-176
Oral bioavailability enhancement of doxazosin mesylate: Nanosuspension versus self-nanoemulsifying drug delivery systems
Background and purpose: Doxazosin mesylate (DOX) is an antihypertensive drug that possesses poor water solubility and, hence, poor release properties. Both nanosuspensions and self-nanoemulsifying drug delivery systems (SNEDDS) are becoming nanotechnology techniques for the enhancement of water solubility of different drugs. Experimental approach: The study's goal was to identify the best drug delivery system able to enhance the release and antihypertensive effect of DOX by comparing the physical characteristics such as particle size, zeta potential, entrapment efficiency, release rate, and main arterial blood pressure of DOX-loaded nanosuspensions and SNEDDS in liquid and solid form. Key results: DOX nanosuspension preparation had a particle size of 385±13 nm, poly-dispersity index of 0.049±3, zeta potential of 50 ± 4 mV and drug release after 20 min (91±0.43 %). Liquid SNEDDS had a droplet size of 224±15 nm, poly-dispersity index of (0.470±0.01), zeta potential of -5±0.10 mV and DR20min of 93±4 %. Solid SEDDS showed particle size of 79±14 nm, poly-dispersity index of 1±0.00, a zeta potential of -18 ±0.26 mv and DR20min of 100 ±2.72 %. Conclusion: Finally, in terms of the mean arterial blood pressure lowering, solid SNEDDS performed better effect than both liquid SNEDDS and nanosuspension (P >0.05).
- 3 November 2023
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 12 (1) , 167-176
Open AccessOral bioavailability enhancement of doxazosin mesylate: Nanosuspension versus self-nanoemulsifying drug delivery systems
Background and purpose: Doxazosin mesylate (DOX) is an antihypertensive drug that possesses poor water solubility and, hence, poor release properties. Both nanosuspensions and self-nanoemulsifying drug delivery systems (SNEDDS) are becoming nanotechnology techniques for the enhancement of water solubility of different drugs. Experimental approach: The study's goal was to identify the best drug delivery system able to enhance the release and antihypertensive effect of DOX by comparing the physical characteristics such as particle size, zeta potential, entrapment efficiency, release rate, and main arterial blood pressure of DOX-loaded nanosuspensions and SNEDDS in liquid and solid form. Key results: DOX nanosuspension preparation had a particle size of 385±13 nm, poly-dispersity index of 0.049±3, zeta potential of 50 ± 4 mV and drug release after 20 min (91±0.43 %). Liquid SNEDDS had a droplet size of 224±15 nm, poly-dispersity index of (0.470±0.01), zeta potential of -5±0.10 mV and DR20min of 93±4 %. Solid SEDDS showed particle size of 79±14 nm, poly-dispersity index of 1±0.00, a zeta potential of -18 ±0.26 mv and DR20min of 100 ±2.72 %. Conclusion: Finally, in terms of the mean arterial blood pressure lowering, solid SNEDDS performed better effect than both liquid SNEDDS and nanosuspension (P >0.05).